Cover Image
市場調查報告書

X染色體脆折症候群:開發中產品分析

Fragile X Syndrome - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200946
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
X染色體脆折症候群:開發中產品分析 Fragile X Syndrome - Pipeline Review, H1 2017
出版日期: 2017年04月11日 內容資訊: 英文 108 Pages
簡介

X染色體脆折症候群特徵是遺傳性的精神遲緩,伴隨X染色體的部分變動,以及健康狀態上受肉體、智力上的限制。病因之一是FMR1遺傳基因的變異。行動方面的症狀有爬行、步行、扭轉相關遲緩,及拍手、咬手,過度、衝動的行動,精神遲緩,言詞、語言遲緩,迴避目光接觸等傾向。肉體的徵兆,有扁平足,關節鬆動,肌肉張力低下,前額、耳朵巨大(也包含下巴肥大),長臉等。日常生活的獨立性改善上,復建是最好的方法。

本報告提供全球各國的X染色體脆折症候群治療用的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品的一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等。

簡介

  • 調查範圍

X染色體脆折症候群概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

X染色體脆折症候群:企業開發中的治療藥

X染色體脆折症候群:大學/機關研究中的治療藥

X染色體脆折症候群:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

X染色體脆折症候群:企業開發中的產品

X染色體脆折症候群:大學/機關研究中的產品

X染色體脆折症候群的治療藥的開發企業

  • Aelis Farma SAS
  • Alcobra Ltd
  • AMO Pharma Limited
  • Confluence Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Marinus Pharmaceuticals, Inc.
  • MI.TO. Technology S.r.L.
  • Neuren Pharmaceuticals Limited
  • Ovid Therapeutics Inc.
  • Sage Therapeutics, Inc.
  • Zynerba Pharmaceuticals, Inc.

X染色體脆折症候群:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

X染色體脆折症候群:最近的開發平台趨勢

X染色體脆折症候群:暫停中的計劃

X染色體脆折症候群:開發中止的產品

X染色體脆折症候群:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9182IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fragile X Syndrome - Overview
    • Fragile X Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Fragile X Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fragile X Syndrome - Companies Involved in Therapeutics Development
    • Aelis Farma SAS
    • AMO Pharma Ltd
    • Anavex Life Sciences Corp
    • Confluence Pharmaceuticals LLC
    • DRI Biosciences Corp
    • Eli Lilly and Company
    • Fulcrum Therapeutics Inc
    • GlaxoSmithKline Plc
    • GW Pharmaceuticals Plc
    • Marinus Pharmaceuticals Inc
    • Neuren Pharmaceuticals Ltd
    • Neuron Biopharma SA
    • Ovid Therapeutics Inc
    • Sage Therapeutics Inc
    • Zynerba Pharmaceuticals Inc
  • Fragile X Syndrome - Drug Profiles
    • acamprosate calcium - Drug Profile
    • ACT-01 - Drug Profile
    • AMO-01 - Drug Profile
    • ANAVEX-273 - Drug Profile
    • Bryostatin-1 - Drug Profile
    • cannabidiol - Drug Profile
    • cercosporamide - Drug Profile
    • Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
    • flindokalner - Drug Profile
    • gaboxadol - Drug Profile
    • ganaxolone - Drug Profile
    • JRP-655 - Drug Profile
    • NNZ-2591 - Drug Profile
    • NST-0076 - Drug Profile
    • SAGE-217 - Drug Profile
    • SGE-872 - Drug Profile
    • Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome - Drug Profile
    • Small Molecule to Activate FMRP for Fragile X Syndrome - Drug Profile
    • Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
    • Small Molecules to Activate Slack Channels for Fragile X Syndrome - Drug Profile
    • Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome - Drug Profile
    • Small Molecules to Block Kv3.1 for Fragile X Syndrome - Drug Profile
    • Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
    • SRT-278 - Drug Profile
    • TC-2153 - Drug Profile
    • trofinetide - Drug Profile
  • Fragile X Syndrome - Dormant Projects
  • Fragile X Syndrome - Discontinued Products
  • Fragile X Syndrome - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Fragile X Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Fragile X Syndrome - Pipeline by Aelis Farma SAS, H1 2017
  • Fragile X Syndrome - Pipeline by AMO Pharma Ltd, H1 2017
  • Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H1 2017
  • Fragile X Syndrome - Pipeline by DRI Biosciences Corp, H1 2017
  • Fragile X Syndrome - Pipeline by Eli Lilly and Company, H1 2017
  • Fragile X Syndrome - Pipeline by Fulcrum Therapeutics Inc, H1 2017
  • Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals Inc, H1 2017
  • Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
  • Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H1 2017
  • Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc, H1 2017
  • Fragile X Syndrome - Pipeline by Sage Therapeutics Inc, H1 2017
  • Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
  • Fragile X Syndrome - Dormant Projects, H1 2017
  • Fragile X Syndrome - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Fragile X Syndrome - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Fragile X Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top